{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:03:41Z","timestamp":1794852221589,"version":"4.9.1"},"reference-count":202,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302421"],"award-info":[{"award-number":["82302421"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The rapid development of DNA- and RNA-editing tools (collectively referred to as gene editing technologies) has caused a paradigm shift in the treatment of human diseases from symptomatic treatment to precision-based medicine. Both DNA-based and RNA-based editing systems, including Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)\u2013derived technologies and newly developed RNA editing tools, have pushed technological frontiers in terms of editing precision, hierarchical control, and reversibility; they have accumulated a growing body of preclinical and clinical evidence across diverse diseases ranging from inherited disorders to cancer, infectious diseases, and neurodegenerative diseases (ND). This review systematically summarizes the core principles and representative advances of DNA-based genome editing and RNA-based transcriptome editing technologies, comprehensively compares the two categories of technical strategies in terms of therapeutic potential, durability of effects, and risk profiles, and further explores the key challenges for achieving long-term safe and efficient in vivo applications, covering core bottlenecks such as delivery efficiency, tissue specificity, genotoxicity, and immunogenicity. Safety assessment has broadened to include tracking genotoxicity and genomic structural variations, whereas delivery systems and tissue specificity are determinant factors for in vivo therapeutic applications. Through the employment of both permanent and reversible editing strategies with high cargo-writing capacity and low integration risk, combined with programmable delivery systems, the therapeutic potential of hard-to-transfect tissues and complex diseases is anticipated to be broadened, opening new paths for clinical translation.<\/jats:p>","DOI":"10.1186\/s43556-026-00456-x","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:19:50Z","timestamp":1776863990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects"],"prefix":"10.1186","volume":"7","author":[{"given":"Rui","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangzheqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"1","key":"456_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/0023677221993895","volume":"56","author":"F Caso","year":"2022","unstructured":"Caso F, Davies B. Base editing and prime editing in laboratory animals. Lab Anim. 2022;56(1):35\u201349. https:\/\/doi.org\/10.1177\/0023677221993895.","journal-title":"Lab Anim"},{"issue":"7785","key":"456_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149\u201357. https:\/\/doi.org\/10.1038\/s41586-019-1711-4.","journal-title":"Nature"},{"issue":"3","key":"456_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","volume":"24","author":"PJ Chen","year":"2023","unstructured":"Chen PJ, Liu DR. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 2023;24(3):161\u201377. https:\/\/doi.org\/10.1038\/s41576-022-00541-1.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"456_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19136-7","volume":"11","author":"IF Schene","year":"2020","unstructured":"Schene IF, Joore IP, Oka R, Mokry M, van Vugt AHM, van Boxtel R, et al. Prime editing for functional repair in patient-derived disease models. Nat Commun. 2020;11(1):5352. https:\/\/doi.org\/10.1038\/s41467-020-19136-7.","journal-title":"Nat Commun"},{"issue":"1","key":"456_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41551-024-01296-2","volume":"9","author":"R Ho\u0142ubowicz","year":"2025","unstructured":"Ho\u0142ubowicz R, Du SW, Felgner J, Smidak R, Choi EH, Palczewska G, et al. Safer and efficient base editing and prime editing via ribonucleoproteins delivered through optimized lipid-nanoparticle formulations. Nat Biomed Eng. 2025;9(1):57\u201378. https:\/\/doi.org\/10.1038\/s41551-024-01296-2.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"456_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02427-2","volume":"22","author":"SH Im","year":"2024","unstructured":"Im SH, Jang M, Park JH, Chung HJ. Finely tuned ionizable lipid nanoparticles for CRISPR\/Cas9 ribonucleoprotein delivery and gene editing. J Nanobiotechnology. 2024;22(1):175. https:\/\/doi.org\/10.1186\/s12951-024-02427-2.","journal-title":"J Nanobiotechnology"},{"key":"456_CR7","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2025.10","volume":"27","author":"B Cetin","year":"2025","unstructured":"Cetin B, Erendor F, Eksi YE, Sanlioglu AD, Sanlioglu S. Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. Expert Rev Mol Med. 2025;27:e16. https:\/\/doi.org\/10.1017\/erm.2025.10.","journal-title":"Expert Rev Mol Med"},{"issue":"6","key":"456_CR8","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/j.ymthe.2025.03.026","volume":"33","author":"D Liu","year":"2025","unstructured":"Liu D, Cao D, Han R. Recent advances in therapeutic gene-editing technologies. Mol Ther. 2025;33(6):2619\u201344. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.026.","journal-title":"Mol Ther"},{"issue":"4","key":"456_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41587-022-01494-w","volume":"41","author":"MG Durrant","year":"2023","unstructured":"Durrant MG, Fanton A, Tycko J, Hinks M, Chandrasekaran SS, Perry NT, et al. Systematic discovery of recombinases for efficient integration of large DNA sequences into the human genome. Nat Biotechnol. 2023;41(4):488\u201399. https:\/\/doi.org\/10.1038\/s41587-022-01494-w.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"456_CR10","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41588-024-01706-w","volume":"56","author":"C Policarpi","year":"2024","unstructured":"Policarpi C, Munaf\u00f2 M, Tsagkris S, Carlini V, Hackett JA. Systematic epigenome editing captures the context-dependent instructive function of chromatin modifications. Nat Genet. 2024;56(6):1168\u201380. https:\/\/doi.org\/10.1038\/s41588-024-01706-w.","journal-title":"Nat Genet"},{"issue":"1","key":"456_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44867-2","volume":"15","author":"J Yu","year":"2024","unstructured":"Yu J, Shin J, Yu J, Kim J, Yu D, Heo WD. Programmable RNA base editing with photoactivatable CRISPR-Cas13. Nat Commun. 2024;15(1):673. https:\/\/doi.org\/10.1038\/s41467-024-44867-2.","journal-title":"Nat Commun"},{"issue":"19","key":"456_CR12","doi-asserted-by":"publisher","first-page":"11926","DOI":"10.1093\/nar\/gkae682","volume":"52","author":"Y N\u00fa\u00f1ez-\u00c1lvarez","year":"2024","unstructured":"N\u00fa\u00f1ez-\u00c1lvarez Y, Espie-Caullet T, Buhagiar G, Rubio-Zulaika A, Alonso-Mara\u00f1\u00f3n J, Luna-P\u00e9rez E, et al. A CRISPR-dCas13 RNA-editing tool to study alternative splicing. Nucleic Acids Res. 2024;52(19):11926\u201339. https:\/\/doi.org\/10.1093\/nar\/gkae682.","journal-title":"Nucleic Acids Res"},{"issue":"6366","key":"456_CR13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","volume":"358","author":"DBT Cox","year":"2017","unstructured":"Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, et al. RNA editing with CRISPR-Cas13. Science. 2017;358(6366):1019\u201327. https:\/\/doi.org\/10.1126\/science.aaq0180.","journal-title":"Science"},{"issue":"45","key":"456_CR14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2408345121","volume":"121","author":"S Kumar","year":"2024","unstructured":"Kumar S, Hsiao YW, Wong VHY, Aubin D, Wang JH, Lisowski L, et al. Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina. Proc Natl Acad Sci U S A. 2024;121(45):e2408345121. https:\/\/doi.org\/10.1073\/pnas.2408345121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"456_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abk2485","volume":"8","author":"JE Powell","year":"2022","unstructured":"Powell JE, Lim CKW, Krishnan R, McCallister TX, Saporito-Magri\u00f1a C, Zeballos MA, et al. Targeted gene silencing in the nervous system with CRISPR-Cas13. Sci Adv. 2022;8(3):eabk2485. https:\/\/doi.org\/10.1126\/sciadv.abk2485.","journal-title":"Sci Adv"},{"issue":"10","key":"456_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100800","volume":"13","author":"M Laurent","year":"2024","unstructured":"Laurent M, Geoffroy M, Pavani G, Guiraud S. CRISPR-based gene therapies: from preclinical to clinical treatments. Cells. 2024;13(10):800. https:\/\/doi.org\/10.3390\/cells13100800.","journal-title":"Cells"},{"key":"456_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2025.1553590","volume":"7","author":"JJ Cabr\u00e9-Romans","year":"2025","unstructured":"Cabr\u00e9-Romans JJ, Cuella-Martin R. CRISPR-dependent base editing as a therapeutic strategy for rare monogenic disorders. Front Genome Ed. 2025;7:1553590. https:\/\/doi.org\/10.3389\/fgeed.2025.1553590.","journal-title":"Front Genome Ed"},{"issue":"7603","key":"456_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420\u20134. https:\/\/doi.org\/10.1038\/nature17946.","journal-title":"Nature"},{"issue":"3","key":"456_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102666","volume":"36","author":"M Raigani","year":"2025","unstructured":"Raigani M, Eftekhari Z, Adeli A, Kazemi-Lomedasht F. Advancing gene editing therapeutics: clinical trials and innovative delivery systems across diverse diseases. Mol Ther Nucleic Acids. 2025;36(3):102666. https:\/\/doi.org\/10.1016\/j.omtn.2025.102666.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"456_CR20","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1007\/s12033-024-01301-8","volume":"67","author":"G Kaur","year":"2025","unstructured":"Kaur G, Arora J, Sodhi AS, Bhatia S, Batra N. Nanotechnology and CRISPR\/Cas-mediated gene therapy strategies: potential role for treating genetic disorders. Mol Biotechnol. 2025;67(10):3800\u201322. https:\/\/doi.org\/10.1007\/s12033-024-01301-8.","journal-title":"Mol Biotechnol"},{"issue":"1","key":"456_CR21","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-03010-6","volume":"26","author":"M Bhagat","year":"2024","unstructured":"Bhagat M, Kamal R, Sharma J, Kaur K, Sharma A, Thakur GS, et al. Gene therapy: towards a new era of medicine. AAPS PharmSciTech. 2024;26(1):17. https:\/\/doi.org\/10.1208\/s12249-024-03010-6.","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"456_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","volume":"41","author":"MTN Yarnall","year":"2023","unstructured":"Yarnall MTN, Ioannidi EI, Schmitt-Ulms C, Krajeski RN, Lim J, Villiger L, et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat Biotechnol. 2023;41(4):500\u201312. https:\/\/doi.org\/10.1038\/s41587-022-01527-4.","journal-title":"Nat Biotechnol"},{"issue":"6096","key":"456_CR23","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816\u201321. https:\/\/doi.org\/10.1126\/science.1225829.","journal-title":"Science"},{"issue":"2","key":"456_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41596-020-00450-9","volume":"16","author":"TP Huang","year":"2021","unstructured":"Huang TP, Newby GA, Liu DR. Precision genome editing using cytosine and adenine base editors in mammalian cells. Nat Protoc. 2021;16(2):1089\u2013128. https:\/\/doi.org\/10.1038\/s41596-020-00450-9.","journal-title":"Nat Protoc"},{"issue":"11","key":"456_CR25","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41551-022-00911-4","volume":"6","author":"JR Davis","year":"2022","unstructured":"Davis JR, Wang X, Witte IP, Huang TP, Levy JM, Raguram A, et al. Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat Biomed Eng. 2022;6(11):1272\u201383. https:\/\/doi.org\/10.1038\/s41551-022-00911-4.","journal-title":"Nat Biomed Eng"},{"issue":"7866","key":"456_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","volume":"595","author":"GA Newby","year":"2021","unstructured":"Newby GA, Yen JS, Woodard KJ, Mayuranathan T, Lazzarotto CR, Li Y, et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature. 2021;595(7866):295\u2013302. https:\/\/doi.org\/10.1038\/s41586-021-03609-w.","journal-title":"Nature"},{"issue":"7859","key":"456_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334. https:\/\/doi.org\/10.1038\/s41586-021-03534-y.","journal-title":"Nature"},{"issue":"1","key":"456_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41593-023-01499-x","volume":"27","author":"WK Li","year":"2024","unstructured":"Li WK, Zhang SQ, Peng WL, Shi YH, Yuan B, Yuan YT, et al. Whole-brain in vivo base editing reverses behavioral changes in Mef2c-mutant mice. Nat Neurosci. 2024;27(1):116\u201328. https:\/\/doi.org\/10.1038\/s41593-023-01499-x.","journal-title":"Nat Neurosci"},{"issue":"1","key":"456_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymthe.2021.05.022","volume":"30","author":"SA Hong","year":"2022","unstructured":"Hong SA, Seo JH, Wi S, Jung ES, Yu J, Hwang GH, et al. In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment. Mol Ther. 2022;30(1):119\u201329. https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.022.","journal-title":"Mol Ther"},{"issue":"5","key":"456_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202200533","volume":"18","author":"M Li","year":"2023","unstructured":"Li M, Zhao Y, Xue X, Zhong J, Lin J, Zhou J, et al. Cas9-orthologue-mediated cytosine and adenine base editors recognizing NNAAAA PAM sequences. Biotechnol J. 2023;18(5):e2200533. https:\/\/doi.org\/10.1002\/biot.202200533.","journal-title":"Biotechnol J"},{"issue":"7699","key":"456_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature26155","volume":"556","author":"JH Hu","year":"2018","unstructured":"Hu JH, Miller SM, Geurts MH, Tang W, Chen L, Sun N, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. 2018;556(7699):57\u201363. https:\/\/doi.org\/10.1038\/nature26155.","journal-title":"Nature"},{"issue":"34","key":"456_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202506644","volume":"12","author":"K Sun","year":"2025","unstructured":"Sun K, Cheng S, Chai N, Mi J, Zhang R, Qian Q, et al. Engineering Adenine Deaminase TadA for Precise and PAM-Flexible Point Mutagenesis and Gradient-Tuning Endogenous Protein Design. Adv Sci (Weinh). 2025;12(34):e06644. https:\/\/doi.org\/10.1002\/advs.202506644.","journal-title":"Adv Sci (Weinh)"},{"issue":"6488","key":"456_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1126\/science.aba8853","volume":"368","author":"RT Walton","year":"2020","unstructured":"Walton RT, Christie KA, Whittaker MN, Kleinstiver BP. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science. 2020;368(6488):290\u20136. https:\/\/doi.org\/10.1126\/science.aba8853.","journal-title":"Science"},{"issue":"1","key":"456_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22295-w","volume":"12","author":"P Liu","year":"2021","unstructured":"Liu P, Liang SQ, Zheng C, Mintzer E, Zhao YG, Ponnienselvan K, et al. Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat Commun. 2021;12(1):2121. https:\/\/doi.org\/10.1038\/s41467-021-22295-w.","journal-title":"Nat Commun"},{"issue":"3","key":"456_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","volume":"40","author":"JW Nelson","year":"2022","unstructured":"Nelson JW, Randolph PB, Shen SP, Everette KA, Chen PJ, Anzalone AV, et al. Engineered pegRNAs improve prime editing efficiency. Nat Biotechnol. 2022;40(3):402\u201310. https:\/\/doi.org\/10.1038\/s41587-021-01039-7.","journal-title":"Nat Biotechnol"},{"issue":"22","key":"456_CR36","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","volume":"184","author":"PJ Chen","year":"2021","unstructured":"Chen PJ, Hussmann JA, Yan J, Knipping F, Ravisankar P, Chen PF, et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell. 2021;184(22):5635-52.e29. https:\/\/doi.org\/10.1016\/j.cell.2021.09.018.","journal-title":"Cell"},{"issue":"1","key":"456_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ymthe.2021.07.011","volume":"30","author":"S Zhi","year":"2022","unstructured":"Zhi S, Chen Y, Wu G, Wen J, Wu J, Liu Q, et al. Dual-AAV delivering split prime editor system for in vivo genome editing. Mol Ther. 2022;30(1):283\u201394. https:\/\/doi.org\/10.1016\/j.ymthe.2021.07.011.","journal-title":"Mol Ther"},{"issue":"1","key":"456_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-024-03257-z","volume":"25","author":"S Mu","year":"2024","unstructured":"Mu S, Chen H, Li Q, Gou S, Liu X, Wang J, et al. Enhancing prime editor flexibility with coiled-coil heterodimers. Genome Biol. 2024;25(1):108. https:\/\/doi.org\/10.1186\/s13059-024-03257-z.","journal-title":"Genome Biol"},{"issue":"6451","key":"456_CR39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1126\/science.aax7063","volume":"365","author":"OO Abudayyeh","year":"2019","unstructured":"Abudayyeh OO, Gootenberg JS, Franklin B, Koob J, Kellner MJ, Ladha A, et al. A cytosine deaminase for programmable single-base RNA editing. Science. 2019;365(6451):382\u20136. https:\/\/doi.org\/10.1126\/science.aax7063.","journal-title":"Science"},{"issue":"7971","key":"456_CR40","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","volume":"619","author":"J Kim","year":"2023","unstructured":"Kim J, Woo S, de Gusmao CM, Zhao B, Chin DH, DiDonato RL, et al. A framework for individualized splice-switching oligonucleotide therapy. Nature. 2023;619(7971):828\u201336. https:\/\/doi.org\/10.1038\/s41586-023-06277-0.","journal-title":"Nature"},{"issue":"654","key":"456_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn0449","volume":"14","author":"Q Xiao","year":"2022","unstructured":"Xiao Q, Xu Z, Xue Y, Xu C, Han L, Liu Y, et al. Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor. Sci Transl Med. 2022;14(654):eabn0449. https:\/\/doi.org\/10.1126\/scitranslmed.abn0449.","journal-title":"Sci Transl Med"},{"issue":"1","key":"456_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64748-6","volume":"16","author":"W Han","year":"2025","unstructured":"Han W, Yuan B, Fan X, Li W, Yuan Y, Zhang Y, et al. Effective in vivo RNA base editing via engineered cytidine deaminase APOBECs fused with PUF proteins. Nat Commun. 2025;16(1):9727. https:\/\/doi.org\/10.1038\/s41467-025-64748-6.","journal-title":"Nat Commun"},{"issue":"1","key":"456_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-024-00397-w","volume":"9","author":"A Dadush","year":"2024","unstructured":"Dadush A, Merdler-Rabinowicz R, Gorelik D, Feiglin A, Buchumenski I, Pal LR, et al. DNA and RNA base editors can correct the majority of pathogenic single nucleotide variants. NPJ Genom Med. 2024;9(1):16. https:\/\/doi.org\/10.1038\/s41525-024-00397-w.","journal-title":"NPJ Genom Med"},{"issue":"6","key":"456_CR44","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41587-021-01180-3","volume":"40","author":"Z Yi","year":"2022","unstructured":"Yi Z, Qu L, Tang H, Liu Z, Liu Y, Tian F, et al. Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo. Nat Biotechnol. 2022;40(6):946\u201355. https:\/\/doi.org\/10.1038\/s41587-021-01180-3.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"456_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-03086-6","volume":"24","author":"Z Yi","year":"2023","unstructured":"Yi Z, Zhao Y, Yi Z, Zhang Y, Tang G, Zhang X, et al. Utilizing AAV-mediated LEAPER 2.0 for programmable RNA editing in non-human primates and nonsense mutation correction in humanized Hurler syndrome mice. Genome Biol. 2023;24(1):243. https:\/\/doi.org\/10.1186\/s13059-023-03086-6.","journal-title":"Genome Biol"},{"issue":"45","key":"456_CR46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2505269122","volume":"122","author":"C Hao","year":"2025","unstructured":"Hao C, Zhang N, Mo O, Chen P, Liu Q, Cheng X, et al. An ADAR2-mimic base editor for efficient C-to-U RNA editing in vivo. Proc Natl Acad Sci U S A. 2025;122(45):e2505269122. https:\/\/doi.org\/10.1073\/pnas.2505269122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"456_CR47","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41587-024-02313-0","volume":"43","author":"P Reautschnig","year":"2025","unstructured":"Reautschnig P, Fruhner C, Wahn N, Wiegand CP, Kragness S, Yung JF, et al. Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA. Nat Biotechnol. 2025;43(4):545\u201357. https:\/\/doi.org\/10.1038\/s41587-024-02313-0.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"456_CR48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.chembiol.2021.07.011","volume":"29","author":"A M\u00e9ndez-Mancilla","year":"2022","unstructured":"M\u00e9ndez-Mancilla A, Wessels HH, Legut M, Kadina A, Mabuchi M, Walker J, et al. Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells. Cell Chem Biol. 2022;29(2):321-7.e4. https:\/\/doi.org\/10.1016\/j.chembiol.2021.07.011.","journal-title":"Cell Chem Biol"},{"issue":"1","key":"456_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-025-07557-3","volume":"8","author":"LE Fry","year":"2025","unstructured":"Fry LE, Major L, Salman A, McDermott LA, Yang J, King AJ, et al. Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration. Commun Biol. 2025;8(1):200. https:\/\/doi.org\/10.1038\/s42003-025-07557-3.","journal-title":"Commun Biol"},{"issue":"1","key":"456_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47140-8","volume":"15","author":"Y Recinos","year":"2024","unstructured":"Recinos Y, Ustianenko D, Yeh YT, Wang X, Jacko M, Yesantharao LV, et al. CRISPR-dCas13d-based deep screening of proximal and distal splicing-regulatory elements. Nat Commun. 2024;15(1):3839. https:\/\/doi.org\/10.1038\/s41467-024-47140-8.","journal-title":"Nat Commun"},{"issue":"1","key":"456_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45795-x","volume":"15","author":"Y Ding","year":"2024","unstructured":"Ding Y, Tous C, Choi J, Chen J, Wong WW. Orthogonal inducible control of Cas13 circuits enables programmable RNA regulation in mammalian cells. Nat Commun. 2024;15(1):1572. https:\/\/doi.org\/10.1038\/s41467-024-45795-x.","journal-title":"Nat Commun"},{"issue":"1","key":"456_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-025-00994-2","volume":"25","author":"SS Garimella","year":"2025","unstructured":"Garimella SS, Minami SA, Khanchandani AN, Abad Santos JC, Schaffer SR, Shah PS. A simplified two-plasmid system for orthogonal control of mammalian gene expression using light-activated CRISPR effector. BMC Biotechnol. 2025;25(1):58. https:\/\/doi.org\/10.1186\/s12896-025-00994-2.","journal-title":"BMC Biotechnol"},{"key":"456_CR53","doi-asserted-by":"publisher","DOI":"10.3791\/68779","volume":"225","author":"JC Abad Santos","year":"2025","unstructured":"Abad Santos JC, Garimella SS, Khanchandani AN, Shah PS. Rapid optimization of a light-inducible system to control mammalian gene expression. J Vis Exp. 2025;225:68779. https:\/\/doi.org\/10.3791\/68779.","journal-title":"J Vis Exp"},{"issue":"7","key":"456_CR54","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/s41596-019-0178-y","volume":"14","author":"LJ Bugaj","year":"2019","unstructured":"Bugaj LJ, Lim WA. High-throughput multicolor optogenetics in microwell plates. Nat Protoc. 2019;14(7):2205\u201328. https:\/\/doi.org\/10.1038\/s41596-019-0178-y.","journal-title":"Nat Protoc"},{"issue":"5","key":"456_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szaf016","volume":"14","author":"J Rainaldi","year":"2025","unstructured":"Rainaldi J, Mali P, Nourreddine S. Emerging clinical applications of ADAR based RNA editing. Stem Cells Transl Med. 2025;14(5):szaf016. https:\/\/doi.org\/10.1093\/stcltm\/szaf016.","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"456_CR56","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41587-019-0178-z","volume":"37","author":"L Qu","year":"2019","unstructured":"Qu L, Yi Z, Zhu S, Wang C, Cao Z, Zhou Z, et al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat Biotechnol. 2019;37(9):1059\u201369. https:\/\/doi.org\/10.1038\/s41587-019-0178-z.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"456_CR57","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","volume":"173","author":"S Konermann","year":"2018","unstructured":"Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell. 2018;173(3):665-76.e14. https:\/\/doi.org\/10.1016\/j.cell.2018.02.033.","journal-title":"Cell"},{"issue":"18","key":"456_CR58","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024;390(18):1649\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2309676.","journal-title":"N Engl J Med"},{"issue":"9","key":"456_CR59","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa2215643","volume":"389","author":"A Sharma","year":"2023","unstructured":"Sharma A, Boelens JJ, Cancio M, Hankins JS, Bhad P, Azizy M, et al. CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease. N Engl J Med. 2023;389(9):820\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2215643.","journal-title":"N Engl J Med"},{"issue":"12","key":"456_CR60","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1016\/j.ymthe.2024.10.018","volume":"32","author":"C Li","year":"2024","unstructured":"Li C, Georgakopoulou A, Paschoudi K, Anderson AK, Huang L, Gil S, et al. Introducing a hemoglobin G-Makassar variant in HSCs by in vivo base editing treats sickle cell disease in mice. Mol Ther. 2024;32(12):4353\u201371. https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.018.","journal-title":"Mol Ther"},{"issue":"6","key":"456_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454.","journal-title":"N Engl J Med"},{"issue":"9","key":"456_CR62","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41575-021-00491-9","volume":"18","author":"CC Paulusma","year":"2021","unstructured":"Paulusma CC, Bosma PJ. Therapeutic base editing in the adult liver. Nat Rev Gastroenterol Hepatol. 2021;18(9):597\u20138. https:\/\/doi.org\/10.1038\/s41575-021-00491-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"22","key":"456_CR63","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med. 2025;392(22):2235\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2504747.","journal-title":"N Engl J Med"},{"issue":"21","key":"456_CR64","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa230991","volume":"390","author":"EA Pierce","year":"2024","unstructured":"Pierce EA, Aleman TS, Jayasundera KT, Ashimatey BS, Kim K, Rashid A, et al. Gene editing for CEP290-associated retinal degeneration. N Engl J Med. 2024;390(21):1972\u201384. https:\/\/doi.org\/10.1056\/NEJMoa230991.","journal-title":"N Engl J Med"},{"issue":"2","key":"456_CR65","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41551-021-00788-9","volume":"6","author":"H Jang","year":"2022","unstructured":"Jang H, Jo DH, Cho CS, Shin JH, Seo JH, Yu G, et al. Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases. Nat Biomed Eng. 2022;6(2):181\u201394. https:\/\/doi.org\/10.1038\/s41551-021-00788-9.","journal-title":"Nat Biomed Eng"},{"issue":"16","key":"456_CR66","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1016\/j.cell.2025.06.038","volume":"188","author":"AA Sousa","year":"2025","unstructured":"Sousa AA, Terrey M, Sakai HA, Simmons CQ, Arystarkhova E, Morsci NS, et al. In vivo prime editing rescues alternating hemiplegia of childhood in mice. Cell. 2025;188(16):4275-94.e23. https:\/\/doi.org\/10.1016\/j.cell.2025.06.038.","journal-title":"Cell"},{"issue":"11","key":"456_CR67","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.ymthe.2021.09.003","volume":"29","author":"A Pickar-Oliver","year":"2021","unstructured":"Pickar-Oliver A, Gough V, Bohning JD, Liu S, Robinson-Hamm JN, Daniels H, et al. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. Mol Ther. 2021;29(11):3243\u201357. https:\/\/doi.org\/10.1016\/j.ymthe.2021.09.003.","journal-title":"Mol Ther"},{"issue":"2","key":"456_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102569","volume":"36","author":"MZ Durbacz","year":"2025","unstructured":"Durbacz MZ, Zhang Y, Li H, Nishiyama T, Sanchez-Ortiz E, McAnally JR, et al. Optimized genomic editing of a common Duchenne muscular dystrophy mutation in patient-derived muscle cells and a new humanized mouse model. Mol Ther Nucleic Acids. 2025;36(2):102569. https:\/\/doi.org\/10.1016\/j.omtn.2025.102569.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"456_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1286","volume":"10","author":"LO Afolabi","year":"2021","unstructured":"Afolabi LO, Afolabi MO, Sani MM, Okunowo WO, Yan D, Chen L, et al. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. Clin Transl Immunol. 2021;10(6):e1286. https:\/\/doi.org\/10.1002\/cti2.1286.","journal-title":"Clin Transl Immunol"},{"key":"456_CR70","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.omtm.2021.04.009","volume":"21","author":"E Alves","year":"2021","unstructured":"Alves E, Taifour S, Dolcetti R, Chee J, Nowak AK, Gaudieri S, et al. Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. Mol Ther Methods Clin Dev. 2021;21:592\u2013606. https:\/\/doi.org\/10.1016\/j.omtm.2021.04.009.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"456_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytox.2020.100049","volume":"3","author":"JJ Freen-van Heeren","year":"2020","unstructured":"Freen-van Heeren JJ. Using CRISPR to enhance T cell effector function for therapeutic applications. Cytokine X. 2020;3(1):100049. https:\/\/doi.org\/10.1016\/j.cytox.2020.100049.","journal-title":"Cytokine X"},{"issue":"6481","key":"456_CR72","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. https:\/\/doi.org\/10.1126\/science.aba7365.","journal-title":"Science"},{"issue":"9","key":"456_CR73","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188\u201398. https:\/\/doi.org\/10.1038\/s41423-021-00749-x.","journal-title":"Cell Mol Immunol"},{"key":"456_CR74","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","volume":"24","author":"CA Chamberlain","year":"2022","unstructured":"Chamberlain CA, Bennett EP, Kverneland AH, Svane IM, Donia M, Met \u00d6. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Mol Ther Oncolytics. 2022;24:417\u201328. https:\/\/doi.org\/10.1016\/j.omto.2022.01.004.","journal-title":"Mol Ther Oncolytics"},{"issue":"7953","key":"456_CR75","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023;615(7953):687\u201396. https:\/\/doi.org\/10.1038\/s41586-022-05531-1.","journal-title":"Nature"},{"key":"456_CR76","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.omtm.2022.03.018","volume":"25","author":"J Kath","year":"2022","unstructured":"Kath J, Du W, Pruene A, Braun T, Thommandru B, Turk R, et al. Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells. Mol Ther Methods Clin Dev. 2022;25:311\u201330. https:\/\/doi.org\/10.1016\/j.omtm.2022.03.018.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7643","key":"456_CR77","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113\u20137. https:\/\/doi.org\/10.1038\/nature21405.","journal-title":"Nature"},{"key":"456_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1379900","volume":"12","author":"D Cappabianca","year":"2024","unstructured":"Cappabianca D, Li J, Zheng Y, Tran C, Kasparek K, Mendez P, et al. Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells. Front Bioeng Biotechnol. 2024;12:1379900. https:\/\/doi.org\/10.3389\/fbioe.2024.1379900.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"456_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13007-6","volume":"10","author":"BR Webber","year":"2019","unstructured":"Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019;10(1):5222. https:\/\/doi.org\/10.1038\/s41467-019-13007-6.","journal-title":"Nat Commun"},{"issue":"20","key":"456_CR80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2427216122","volume":"122","author":"NW Engel","year":"2025","unstructured":"Engel NW, Steinfeld I, Ryan D, Anupindi K, Kim S, Wellhausen N, et al. Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR\/Cas9 nuclease-engineered T cells. Proc Natl Acad Sci U S A. 2025;122(20):e2427216122. https:\/\/doi.org\/10.1073\/pnas.2427216122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7681","key":"456_CR81","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, et al. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464\u201371. https:\/\/doi.org\/10.1038\/nature24644.","journal-title":"Nature"},{"issue":"12","key":"456_CR82","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","volume":"35","author":"C Georgiadis","year":"2021","unstructured":"Georgiadis C, Rasaiyaah J, Gkazi SA, Preece R, Etuk A, Christi A, et al. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia. 2021;35(12):3466\u201381. https:\/\/doi.org\/10.1038\/s41375-021-01282-6.","journal-title":"Leukemia"},{"issue":"10","key":"456_CR83","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389(10):899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa2300709.","journal-title":"N Engl J Med"},{"issue":"1","key":"456_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15(1):8439. https:\/\/doi.org\/10.1038\/s41467-024-52388-1.","journal-title":"Nat Commun"},{"key":"456_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1231916","volume":"14","author":"A Mac Donald","year":"2023","unstructured":"Mac Donald A, Guipouy D, Lemieux W, Harvey M, Bordeleau LJ, Guay D, et al. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. Front Immunol. 2023;14:1231916. https:\/\/doi.org\/10.3389\/fimmu.2023.1231916.","journal-title":"Front Immunol"},{"issue":"2","key":"456_CR86","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, et al. Metabolic reprogramming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell. 2020;27(2):224-37.e6. https:\/\/doi.org\/10.1016\/j.stem.2020.05.008.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"456_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28900-w","volume":"13","author":"J Yin","year":"2022","unstructured":"Yin J, Lu R, Xin C, Wang Y, Ling X, Li D, et al. Cas9 exo-endonuclease eliminates chromosomal translocations during genome editing. Nat Commun. 2022;13(1):1204. https:\/\/doi.org\/10.1038\/s41467-022-28900-w.","journal-title":"Nat Commun"},{"issue":"10","key":"456_CR88","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108. https:\/\/doi.org\/10.1038\/s41423-024-01207-0.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"456_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discov. 2024;10(1):318. https:\/\/doi.org\/10.1038\/s41420-024-02077-1.","journal-title":"Cell Death Discov"},{"issue":"2","key":"456_CR90","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"456_CR91","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","volume":"181","author":"TR Abbott","year":"2020","unstructured":"Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell. 2020;181(4):865-76.e12. https:\/\/doi.org\/10.1016\/j.cell.2020.04.020.","journal-title":"Cell"},{"issue":"1","key":"456_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30546-7","volume":"13","author":"L Zeng","year":"2022","unstructured":"Zeng L, Liu Y, Nguyenla XH, Abbott TR, Han M, Zhu Y, et al. Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro. Nat Commun. 2022;13(1):2766. https:\/\/doi.org\/10.1038\/s41467-022-30546-7.","journal-title":"Nat Commun"},{"issue":"4","key":"456_CR93","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jhep.2023.01.017","volume":"78","author":"F Zoulim","year":"2023","unstructured":"Zoulim F, Testoni B. Eliminating cccDNA to cure hepatitis B virus infection. J Hepatol. 2023;78(4):677\u201380. https:\/\/doi.org\/10.1016\/j.jhep.2023.01.017.","journal-title":"J Hepatol"},{"key":"456_CR94","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.omtm.2020.11.014","volume":"20","author":"D Stone","year":"2020","unstructured":"Stone D, Long KR, Loprieno MA, De Silva Feelixge HS, Kenkel EJ, Liley RM, et al. CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. Mol Ther Methods Clin Dev. 2020;20:258\u201375. https:\/\/doi.org\/10.1016\/j.omtm.2020.11.014.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"456_CR95","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02888-21","volume":"13","author":"MG Martinez","year":"2022","unstructured":"Martinez MG, Combe E, Inchauspe A, Mangeot PE, Delberghe E, Chapus F, et al. CRISPR-Cas9 targeting of hepatitis B virus covalently closed circular DNA generates transcriptionally active episomal variants. MBio. 2022;13(2):e0288821. https:\/\/doi.org\/10.1128\/mbio.02888-21.","journal-title":"MBio"},{"key":"456_CR96","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.omtn.2023.02.001","volume":"31","author":"D Kostyushev","year":"2023","unstructured":"Kostyushev D, Kostyusheva A, Brezgin S, Ponomareva N, Zakirova NF, Egorshina A, et al. Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9. Mol Ther Nucleic Acids. 2023;31:482\u201393. https:\/\/doi.org\/10.1016\/j.omtn.2023.02.001.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"456_CR97","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","volume":"69","author":"C Ko","year":"2018","unstructured":"Ko C, Chakraborty A, Chou WM, Hasreiter J, Wettengel JM, Stadler D, et al. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. J Hepatol. 2018;69(6):1231\u201341. https:\/\/doi.org\/10.1016\/j.jhep.2018.08.012.","journal-title":"J Hepatol"},{"key":"456_CR98","doi-asserted-by":"publisher","unstructured":"Kostyusheva AP, Brezgin SA, Ponomareva NI, Goptar IA, Nikiforova AV, Gegechkori VI, et al. Antiviral activity of CRISPR\/Cas9 ribonucleoprotein complexes on a hepatitis B virus model in vivo. Mol Biol (Mosk). 2022;56:816\u201322. https:\/\/doi.org\/10.31857\/S002689842206012X.","DOI":"10.31857\/S002689842206012X"},{"issue":"1","key":"456_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.102112","volume":"35","author":"EM Smekalova","year":"2023","unstructured":"Smekalova EM, Martinez MG, Combe E, Kumar A, Dejene S, Leboeuf D, et al. Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo. Mol Ther Nucleic Acids. 2023;35(1):102112. https:\/\/doi.org\/10.1016\/j.omtn.2023.102112.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"456_CR100","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2024.05.025","volume":"81","author":"LC McCoullough","year":"2024","unstructured":"McCoullough LC, Fareh M, Hu W, Sozzi V, Makhlouf C, Droungas Y, et al. CRISPR-Cas13b-mediated suppression of HBV replication and protein expression. J Hepatol. 2024;81(5):794\u2013805. https:\/\/doi.org\/10.1016\/j.jhep.2024.05.025.","journal-title":"J Hepatol"},{"issue":"3","key":"456_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102282","volume":"35","author":"A Bellizzi","year":"2024","unstructured":"Bellizzi A, \u00c7ak\u0131r S, Donadoni M, Sariyer R, Liao S, Liu H, et al. Suppression of HSV-1 infection and viral reactivation by CRISPR-Cas9 gene editing in 2D and 3D culture models. Mol Ther Nucleic Acids. 2024;35(3):102282. https:\/\/doi.org\/10.1016\/j.omtn.2024.102282.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"456_CR102","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41587-020-00781-8","volume":"39","author":"D Yin","year":"2021","unstructured":"Yin D, Ling S, Wang D, Dai Y, Jiang H, Zhou X, et al. Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice. Nat Biotechnol. 2021;39(5):567\u201377. https:\/\/doi.org\/10.1038\/s41587-020-00781-8.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"456_CR103","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1016\/j.ymthe.2023.08.021","volume":"31","author":"A Wei","year":"2023","unstructured":"Wei A, Yin D, Zhai Z, Ling S, Le H, Tian L, et al. In vivo CRISPR gene editing in patients with herpetic stromal keratitis. Mol Ther. 2023;31(11):3163\u201375. https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.021.","journal-title":"Mol Ther"},{"issue":"3","key":"456_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101303","volume":"32","author":"N Amrani","year":"2024","unstructured":"Amrani N, Luk K, Singh P, Shipley M, Isik M, Donadoni M, et al. CRISPR-Cas9-mediated genome editing delivered by a single AAV9 vector inhibits HSV-1 reactivation in a latent rabbit keratitis model. Mol Ther Methods Clin Dev. 2024;32(3):101303. https:\/\/doi.org\/10.1016\/j.omtm.2024.101303.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"456_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00069","volume":"9","author":"Q Xiao","year":"2019","unstructured":"Xiao Q, Guo D, Chen S. Application of CRISPR\/Cas9-based gene editing in HIV-1\/AIDS therapy. Front Cell Infect Microbiol. 2019;9:69. https:\/\/doi.org\/10.3389\/fcimb.2019.00069.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"456_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.imj.2025.100215","volume":"4","author":"Q Mao","year":"2025","unstructured":"Mao Q, Li L, Wen H. Beyond monotherapy: combination therapies for HIV-1 cure through joint application of neutralizing antibodies, genome editing, and reservoir management. Infect Med Beijing. 2025;4(4):100215. https:\/\/doi.org\/10.1016\/j.imj.2025.100215.","journal-title":"Infect Med Beijing"},{"issue":"19","key":"456_CR107","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2217887120","volume":"120","author":"PK Dash","year":"2023","unstructured":"Dash PK, Chen C, Kaminski R, Su H, Mancuso P, Sillman B, et al. CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice. Proc Natl Acad Sci U S A. 2023;120(19):e2217887120. https:\/\/doi.org\/10.1073\/pnas.2217887120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5\u20136","key":"456_CR108","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41434-023-00410-4","volume":"31","author":"TH Burdo","year":"2024","unstructured":"Burdo TH, Chen C, Kaminski R, Sariyer IK, Mancuso P, Donadoni M, et al. Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates. Gene Ther. 2024;31(5\u20136):224\u201333. https:\/\/doi.org\/10.1038\/s41434-023-00410-4.","journal-title":"Gene Ther"},{"issue":"2","key":"456_CR109","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41587-023-01759-y","volume":"42","author":"YE Gencay","year":"2024","unstructured":"Gencay YE, Jasinskyt\u0117 D, Robert C, Semsey S, Mart\u00ednez V, Petersen A\u00d8, et al. Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice. Nat Biotechnol. 2024;42(2):265\u201374. https:\/\/doi.org\/10.1038\/s41587-023-01759-y.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"456_CR110","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1021\/acssynbio.2c00465","volume":"12","author":"WH Yang","year":"2023","unstructured":"Yang WH, Torraca V, Brown R, Fa-Arun J, Miles SL, Oyarz\u00fan DA, et al. P1 bacteriophage-enabled delivery of CRISPR-Cas9 antimicrobial activity against Shigella flexneri. ACS Synth Biol. 2023;12(3):709\u201321. https:\/\/doi.org\/10.1021\/acssynbio.2c00465.","journal-title":"ACS Synth Biol"},{"issue":"4","key":"456_CR111","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","volume":"28","author":"CKW Lim","year":"2020","unstructured":"Lim CKW, Gapinske M, Brooks AK, Woods WS, Powell JE, Zeballos CMA, et al. Treatment of a mouse model of ALS by in vivo base editing. Mol Ther. 2020;28(4):1177\u201389. https:\/\/doi.org\/10.1016\/j.ymthe.2020.01.005.","journal-title":"Mol Ther"},{"issue":"5","key":"456_CR112","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41434-022-00375-w","volume":"30","author":"YA Chen","year":"2023","unstructured":"Chen YA, Kankel MW, Hana S, Lau SK, Zavodszky MI, McKissick O, et al. In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model. Gene Ther. 2023;30(5):443\u201354. https:\/\/doi.org\/10.1038\/s41434-022-00375-w.","journal-title":"Gene Ther"},{"issue":"1","key":"456_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33332-7","volume":"13","author":"KE Meijboom","year":"2022","unstructured":"Meijboom KE, Abdallah A, Fordham NP, Nagase H, Rodriguez T, Kraus C, et al. CRISPR\/Cas9-mediated excision of ALS\/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Nat Commun. 2022;13(1):6286. https:\/\/doi.org\/10.1038\/s41467-022-33332-7.","journal-title":"Nat Commun"},{"issue":"1","key":"456_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55550-x","volume":"16","author":"L Kempthorne","year":"2025","unstructured":"Kempthorne L, Vaizoglu D, Cammack AJ, Carcol\u00e9 M, Roberts MJ, Mikheenko A, et al. Dual-targeting CRISPR-CasRx reduces C9orf72 ALS\/FTD sense and antisense repeat RNAs in vitro and in vivo. Nat Commun. 2025;16(1):459. https:\/\/doi.org\/10.1038\/s41467-024-55550-x.","journal-title":"Nat Commun"},{"issue":"1","key":"456_CR115","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/crispr.2021.0025","volume":"5","author":"HH Yoon","year":"2022","unstructured":"Yoon HH, Ye S, Lim S, Jo A, Lee H, Hong F, et al. CRISPR-Cas9 gene editing protects from the A53T-SNCA overexpression-induced pathology of Parkinson\u2019s disease in vivo. CRISPR J. 2022;5(1):95\u2013108. https:\/\/doi.org\/10.1089\/crispr.2021.0025.","journal-title":"CRISPR J"},{"issue":"1\u20132","key":"456_CR116","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1089\/hum.2020.323","volume":"33","author":"SR Oikemus","year":"2022","unstructured":"Oikemus SR, Pfister EL, Sapp E, Chase KO, Kennington LA, Hudgens E, et al. Allele-specific knockdown of mutant huntingtin protein via editing at coding region single nucleotide polymorphism heterozygosities. Hum Gene Ther. 2022;33(1\u20132):25\u201336. https:\/\/doi.org\/10.1089\/hum.2020.323.","journal-title":"Hum Gene Ther"},{"issue":"12","key":"456_CR117","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1093\/brain\/awaf244","volume":"148","author":"B Kim","year":"2025","unstructured":"Kim B, Yuk M, Park M, Ryu H, Park J, Yu H, et al. CRISPR editing of miR-33 restores ApoE lipidation and amyloid-\u03b2 metabolism in ApoE4 sporadic Alzheimer\u2019s disease. Brain. 2025;148(12):4400\u201315. https:\/\/doi.org\/10.1093\/brain\/awaf244.","journal-title":"Brain"},{"issue":"23","key":"456_CR118","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","volume":"391","author":"M Fontana","year":"2024","unstructured":"Fontana M, Solomon SD, Kachadourian J, Walsh L, Rocha R, Lebwohl D, et al. CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy. N Engl J Med. 2024;391(23):2231\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2412309.","journal-title":"N Engl J Med"},{"issue":"5","key":"456_CR119","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa2309149","volume":"390","author":"HJ Longhurst","year":"2024","unstructured":"Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, et al. CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema. N Engl J Med. 2024;390(5):432\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2309149.","journal-title":"N Engl J Med"},{"key":"456_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:1143157. https:\/\/doi.org\/10.3389\/fbioe.2023.1143157.","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"456_CR121","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","volume":"42","author":"M Fiumara","year":"2024","unstructured":"Fiumara M, Ferrari S, Omer-Javed A, Beretta S, Albano L, Canarutto D, et al. Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat Biotechnol. 2024;42(6):877\u201391. https:\/\/doi.org\/10.1038\/s41587-023-01915-4.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"456_CR122","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","volume":"53","author":"ML Leibowitz","year":"2021","unstructured":"Leibowitz ML, Papathanasiou S, Doerfler PA, Blaine LJ, Sun L, Yao Y, et al. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. Nat Genet. 2021;53(6):895\u2013905. https:\/\/doi.org\/10.1038\/s41588-021-00838-7.","journal-title":"Nat Genet"},{"issue":"42","key":"456_CR123","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo7676","volume":"8","author":"SH Park","year":"2022","unstructured":"Park SH, Cao M, Pan Y, Davis TH, Saxena L, Deshmukh H, et al. Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing. Sci Adv. 2022;8(42):eabo7676. https:\/\/doi.org\/10.1126\/sciadv.abo7676.","journal-title":"Sci Adv"},{"issue":"6","key":"456_CR124","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","volume":"28","author":"G Turchiano","year":"2021","unstructured":"Turchiano G, Andrieux G, Klermund J, Blattner G, Pennucci V, El Gaz M, et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell. 2021;28(6):1136-47.e5. https:\/\/doi.org\/10.1016\/j.stem.2021.02.002.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"456_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41240-7","volume":"14","author":"B Bestas","year":"2023","unstructured":"Bestas B, Wimberger S, Degtev D, Madsen A, Rottner AK, Karlsson F, et al. A type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo. Nat Commun. 2023;14(1):5474. https:\/\/doi.org\/10.1038\/s41467-023-41240-7.","journal-title":"Nat Commun"},{"issue":"1","key":"456_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15887-5","volume":"11","author":"Y Yu","year":"2020","unstructured":"Yu Y, Leete TC, Born DA, Young L, Barrera LA, Lee SJ, et al. Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity. Nat Commun. 2020;11(1):2052. https:\/\/doi.org\/10.1038\/s41467-020-15887-5.","journal-title":"Nat Commun"},{"issue":"7","key":"456_CR127","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1016\/j.ymthe.2022.04.010","volume":"30","author":"J Zhou","year":"2022","unstructured":"Zhou J, Liu Y, Wei Y, Zheng S, Gou S, Chen T, et al. Eliminating predictable DNA off-target effects of cytosine base editor by using dual guiders including sgRNA and TALE. Mol Ther. 2022;30(7):2443\u201351. https:\/\/doi.org\/10.1016\/j.ymthe.2022.04.010.","journal-title":"Mol Ther"},{"issue":"1","key":"456_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28442-1","volume":"13","author":"J Ferreira Da Silva","year":"2022","unstructured":"Ferreira Da Silva J, Oliveira GP, Arasa-Verge EA, Kagiou C, Moretton A, Timelthaler G, et al. Prime editing efficiency and fidelity are enhanced in the absence of mismatch repair. Nat Commun. 2022;13(1):760. https:\/\/doi.org\/10.1038\/s41467-022-28442-1.","journal-title":"Nat Commun"},{"issue":"2","key":"456_CR129","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","volume":"42","author":"JR Davis","year":"2024","unstructured":"Davis JR, Banskota S, Levy JM, Newby GA, Wang X, Anzalone AV, et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat Biotechnol. 2024;42(2):253\u201364. https:\/\/doi.org\/10.1038\/s41587-023-01758-z.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"456_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26830-7","volume":"12","author":"CH Hakim","year":"2021","unstructured":"Hakim CH, Kumar SRP, P\u00e9rez-L\u00f3pez DO, Wasala NB, Zhang D, Yue Y, et al. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat Commun. 2021;12(1):6769. https:\/\/doi.org\/10.1038\/s41467-021-26830-7.","journal-title":"Nat Commun"},{"issue":"8","key":"456_CR131","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.ymthe.2023.06.019","volume":"31","author":"EC Stahl","year":"2023","unstructured":"Stahl EC, Sabo JK, Kang MH, Allen R, Applegate E, Kim SE, et al. Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs. Mol Ther. 2023;31(8):2422\u201338. https:\/\/doi.org\/10.1016\/j.ymthe.2023.06.019.","journal-title":"Mol Ther"},{"issue":"7","key":"456_CR132","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/ijc.32994","volume":"147","author":"JY Huang","year":"2020","unstructured":"Huang JY, Luu HN, Butler LM, Midttun \u00d8, Ulvik A, Wang R, et al. A prospective evaluation of serum methionine-related metabolites in relation to pancreatic cancer risk in two prospective cohort studies. Int J Cancer. 2020;147(7):1917\u201327. https:\/\/doi.org\/10.1002\/ijc.32994.","journal-title":"Int J Cancer"},{"issue":"7","key":"456_CR133","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24(7):927\u201330. https:\/\/doi.org\/10.1038\/s41591-018-0049-z.","journal-title":"Nat Med"},{"issue":"7555","key":"456_CR134","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature14493","volume":"522","author":"CZ Zhang","year":"2015","unstructured":"Zhang CZ, Spektor A, Cornils H, Francis JM, Jackson EK, Liu S, et al. Chromothripsis from DNA damage in micronuclei. Nature. 2015;522(7555):179\u201384. https:\/\/doi.org\/10.1038\/nature14493.","journal-title":"Nature"},{"issue":"1","key":"456_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28244-5","volume":"13","author":"I H\u00f6ijer","year":"2022","unstructured":"H\u00f6ijer I, Emmanouilidou A, \u00d6stlund R, van Schendel R, Bozorgpana S, Tijsterman M, et al. CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations. Nat Commun. 2022;13(1):627. https:\/\/doi.org\/10.1038\/s41467-022-28244-5.","journal-title":"Nat Commun"},{"issue":"19","key":"456_CR136","doi-asserted-by":"publisher","first-page":"11128","DOI":"10.1093\/nar\/gkac887","volume":"50","author":"J Wu","year":"2022","unstructured":"Wu J, Zou Z, Liu Y, Liu X, Zhangding Z, Xu M, et al. CRISPR\/Cas9-induced structural variations expand in T lymphocytes in vivo. Nucleic Acids Res. 2022;50(19):11128\u201337. https:\/\/doi.org\/10.1093\/nar\/gkac887.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"456_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28135-9","volume":"13","author":"SQ Liang","year":"2022","unstructured":"Liang SQ, Liu P, Smith JL, Mintzer E, Maitland S, Dong X, et al. Genome-wide detection of CRISPR editing in vivo using GUIDE-tag. Nat Commun. 2022;13(1):437. https:\/\/doi.org\/10.1038\/s41467-022-28135-9.","journal-title":"Nat Commun"},{"issue":"1","key":"456_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35086-8","volume":"13","author":"Z Yu","year":"2022","unstructured":"Yu Z, Lu Z, Li J, Wang Y, Wu P, Li Y, et al. PEAC-seq adopts prime editor to detect CRISPR off-target and DNA translocation. Nat Commun. 2022;13(1):7545. https:\/\/doi.org\/10.1038\/s41467-022-35086-8.","journal-title":"Nat Commun"},{"issue":"6","key":"456_CR139","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41592-023-01859-2","volume":"20","author":"SQ Liang","year":"2023","unstructured":"Liang SQ, Liu P, Ponnienselvan K, Suresh S, Chen Z, Kramme C, et al. Genome-wide profiling of prime editor off-target sites in vitro and in vivo using PE-tag. Nat Methods. 2023;20(6):898\u2013907. https:\/\/doi.org\/10.1038\/s41592-023-01859-2.","journal-title":"Nat Methods"},{"issue":"1","key":"456_CR140","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41551-024-01277-5","volume":"9","author":"GH Hwang","year":"2025","unstructured":"Hwang GH, Lee SH, Oh M, Kim S, Habib O, Jang HK, et al. Large DNA deletions occur during DNA repair at 20-fold lower frequency for base editors and prime editors than for Cas9 nucleases. Nat Biomed Eng. 2025;9(1):79\u201392. https:\/\/doi.org\/10.1038\/s41551-024-01277-5.","journal-title":"Nat Biomed Eng"},{"issue":"12","key":"456_CR141","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1101\/gr.275770.121","volume":"31","author":"I Buchumenski","year":"2021","unstructured":"Buchumenski I, Roth SH, Kopel E, Katsman E, Feiglin A, Levanon EY, et al. Global quantification exposes abundant low-level off-target activity by base editors. Genome Res. 2021;31(12):2354\u201361. https:\/\/doi.org\/10.1101\/gr.275770.121.","journal-title":"Genome Res"},{"issue":"3","key":"456_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101506","volume":"33","author":"SS Najera","year":"2025","unstructured":"Najera SS, Nicastri A, Bing S, Sajib AM, Ternette N, Mazor R. AAV2 delivery of the saCas9 gene results in presentation of an HLA-A\u221702:01-restricted T cell epitope potent to induce T cell cytotoxicity. Mol Ther Methods Clin Dev. 2025;33(3):101506. https:\/\/doi.org\/10.1016\/j.omtm.2025.101506.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"456_CR143","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31927","volume":"14","author":"AM Joseph","year":"2022","unstructured":"Joseph AM, Karas M, Ramadan Y, Joubran E, Jacobs RJ. Ethical perspectives of therapeutic human genome editing from multiple and diverse viewpoints: a scoping review. Cureus. 2022;14(11):e31927. https:\/\/doi.org\/10.7759\/cureus.31927.","journal-title":"Cureus"},{"issue":"8","key":"456_CR144","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36(8):765\u201371. https:\/\/doi.org\/10.1038\/nbt.4192.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"456_CR145","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249\u201354. https:\/\/doi.org\/10.1038\/s41591-018-0326-x.","journal-title":"Nat Med"},{"issue":"1","key":"456_CR146","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1265293","volume":"5","author":"E Hanna","year":"2017","unstructured":"Hanna E, R\u00e9muzat C, Auquier P, Toumi M. Gene therapies development: slow progress and promising prospect. J Mark Access Health Policy. 2017;5(1):1265293. https:\/\/doi.org\/10.1080\/20016689.2017.1265293.","journal-title":"J Mark Access Health Policy"},{"issue":"9","key":"456_CR147","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/2326-6066.CIR-24-0482","volume":"12","author":"JK Jadlowsky","year":"2024","unstructured":"Jadlowsky JK, Chang JF, Spencer DH, Warrington JM, Levine BL, June CH, et al. Regulatory considerations for genome-edited T-cell therapies. Cancer Immunol Res. 2024;12(9):1132\u20135. https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0482.","journal-title":"Cancer Immunol Res"},{"key":"456_CR148","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.reth.2024.06.005","volume":"26","author":"H Mizoguchi","year":"2024","unstructured":"Mizoguchi H, Zhang AJ, Gupta PK, Komuro M, Cheun WK, Chiu CW, et al. Regulatory systems and requirements for clinical trials of AAV-based gene therapies - perspectives from six Asian countries or regions: report from the 6th Asia Partnership Conference of Regenerative Medicine - April 20, 2023. Regen Ther. 2024;26:334\u201345. https:\/\/doi.org\/10.1016\/j.reth.2024.06.005.","journal-title":"Regen Ther"},{"issue":"21\u201322","key":"456_CR149","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1089\/hum.2022.090","volume":"33","author":"JS Moffit","year":"2022","unstructured":"Moffit JS, Blanset DL, Lynch JL, MacLachlan TK, Meyer KE, Ponce R, et al. Regulatory consideration for the nonclinical safety assessment of gene therapies. Hum Gene Ther. 2022;33(21\u201322):1126\u201341. https:\/\/doi.org\/10.1089\/hum.2022.090.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"456_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101785","volume":"13","author":"P Toofan","year":"2025","unstructured":"Toofan P, Singh M, Brooks A, McLuckie K. Non-clinical safety considerations on genome editing using the CRISPR\/Cas system. Genes Dis. 2025;13(2):101785. https:\/\/doi.org\/10.1016\/j.gendis.2025.101785.","journal-title":"Genes Dis"},{"key":"456_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00043","volume":"10","author":"M Romano","year":"2019","unstructured":"Romano M, Fanelli G, Albany CJ, Giganti G, Lombardi G. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front Immunol. 2019;10:43. https:\/\/doi.org\/10.3389\/fimmu.2019.00043.","journal-title":"Front Immunol"},{"issue":"3","key":"456_CR152","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","volume":"20","author":"C Raffin","year":"2020","unstructured":"Raffin C, Vo LT, Bluestone JA. Treg cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20(3):158\u201372. https:\/\/doi.org\/10.1038\/s41577-019-0232-6.","journal-title":"Nat Rev Immunol"},{"key":"456_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1626067","volume":"12","author":"PU Dinh","year":"2025","unstructured":"Dinh PU, Mihalcik L. Nonclinical regulatory considerations for investigational new drug applications for regulatory T cell therapies. Front Med Lausanne. 2025;12:1626067. https:\/\/doi.org\/10.3389\/fmed.2025.1626067.","journal-title":"Front Med Lausanne"},{"issue":"4","key":"456_CR154","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3343\/alm.2023.0382","volume":"44","author":"NK Lee","year":"2024","unstructured":"Lee NK, Chang JW. Manufacturing cell and gene therapies: challenges in clinical translation. Ann Lab Med. 2024;44(4):314\u201323. https:\/\/doi.org\/10.3343\/alm.2023.0382.","journal-title":"Ann Lab Med"},{"issue":"2","key":"456_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101250","volume":"32","author":"J Dias","year":"2024","unstructured":"Dias J, Garcia J, Agliardi G, Roddie C. CAR-T cell manufacturing landscape\u2014lessons from the past decade and considerations for early clinical development. Mol Ther Methods Clin Dev. 2024;32(2):101250. https:\/\/doi.org\/10.1016\/j.omtm.2024.101250.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10\u201311","key":"456_CR156","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41434-023-00419-9","volume":"30","author":"CH Wong","year":"2023","unstructured":"Wong CH, Li D, Wang N, Gruber J, Lo AW, Conti RM. The estimated annual financial impact of gene therapy in the United States. Gene Ther. 2023;30(10\u201311):761\u201373. https:\/\/doi.org\/10.1038\/s41434-023-00419-9.","journal-title":"Gene Ther"},{"issue":"12","key":"456_CR157","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0118","volume":"13","author":"S Phares","year":"2024","unstructured":"Phares S, Trusheim M, Emond SK, Pearson SD. Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States. J Comp Eff Res. 2024;13(12):e240118. https:\/\/doi.org\/10.57264\/cer-2024-0118.","journal-title":"J Comp Eff Res"},{"issue":"10","key":"456_CR158","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.tibtech.2023.04.002","volume":"41","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Dalby PA. Challenges in scaling up AAV-based gene therapy manufacturing. Trends Biotechnol. 2023;41(10):1268\u201381. https:\/\/doi.org\/10.1016\/j.tibtech.2023.04.002.","journal-title":"Trends Biotechnol"},{"issue":"2","key":"456_CR159","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota S, Raguram A, Suh S, Du SW, Davis JR, Choi EH, et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell. 2022;185(2):250-65.e16. https:\/\/doi.org\/10.1016\/j.cell.2021.12.021.","journal-title":"Cell"},{"issue":"6656","key":"456_CR160","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.ade6967","volume":"381","author":"L Breda","year":"2023","unstructured":"Breda L, Papp TE, Triebwasser MP, Yadegari A, Fedorky MT, Tanaka N, et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science. 2023;381(6656):436\u201343. https:\/\/doi.org\/10.1126\/science.ade6967.","journal-title":"Science"},{"issue":"15","key":"456_CR161","doi-asserted-by":"publisher","first-page":"8732","DOI":"10.1093\/nar\/gkab686","volume":"49","author":"M Liu","year":"2021","unstructured":"Liu M, Zhang W, Xin C, Yin J, Shang Y, Ai C, et al. Global detection of DNA repair outcomes induced by CRISPR-Cas9. Nucleic Acids Res. 2021;49(15):8732\u201342. https:\/\/doi.org\/10.1093\/nar\/gkab686.","journal-title":"Nucleic Acids Res"},{"key":"456_CR162","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","volume":"341","author":"M Estap\u00e9 Senti","year":"2022","unstructured":"Estap\u00e9 Senti M, de Jongh CA, Dijkxhoorn K, Verhoef JJF, Szebeni J, Storm G, et al. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. J Control Release. 2022;341:475\u201386. https:\/\/doi.org\/10.1016\/j.jconrel.2021.11.042.","journal-title":"J Control Release"},{"issue":"8","key":"456_CR163","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju Y, Lee WS, Pilkington EH, Kelly HG, Li S, Selva KJ, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano. 2022;16(8):11769\u201380. https:\/\/doi.org\/10.1021\/acsnano.2c04543.","journal-title":"ACS Nano"},{"key":"456_CR164","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jconrel.2023.06.027","volume":"360","author":"H Takata","year":"2023","unstructured":"Takata H, Shimizu T, Yamade R, Elsadek NE, Emam SE, Ando H, et al. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route. J Control Release. 2023;360:285\u201392. https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.027.","journal-title":"J Control Release"},{"issue":"3","key":"456_CR165","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ymthe.2024.01.024","volume":"32","author":"M Drouyer","year":"2024","unstructured":"Drouyer M, Merjane J, Nazareth D, Knight M, Scott S, Liao SH, et al. Development of CNS tropic AAV1-like variants with reduced liver-targeting following systemic administration in mice. Mol Ther. 2024;32(3):818\u201336. https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.024.","journal-title":"Mol Ther"},{"issue":"1","key":"456_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52149-0","volume":"15","author":"TF Shay","year":"2024","unstructured":"Shay TF, Jang S, Brittain TJ, Chen X, Walker B, Tebbutt C, et al. Human cell surface-AAV interactomes identify LRP6 as blood-brain barrier transcytosis receptor and immune cytokine IL3 as AAV9 binder. Nat Commun. 2024;15(1):7853. https:\/\/doi.org\/10.1038\/s41467-024-52149-0.","journal-title":"Nat Commun"},{"issue":"8","key":"456_CR167","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1261\/rna.079173.122","volume":"28","author":"SH Chan","year":"2022","unstructured":"Chan SH, Whipple JM, Dai N, Kelley TM, Withers K, Tzertzinis G, et al. RNase H-based analysis of synthetic mRNA 5\u2032 cap incorporation. RNA. 2022;28(8):1144\u201355. https:\/\/doi.org\/10.1261\/rna.079173.122.","journal-title":"RNA"},{"issue":"1","key":"456_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02550-4","volume":"21","author":"X Li","year":"2024","unstructured":"Li X, Gu J, Wu H, Xie Y. Pilot-scale process development for recombinant adeno-associated virus (rAAV) production based on high-density Sf9 cell culture. Virol J. 2024;21(1):281. https:\/\/doi.org\/10.1186\/s12985-024-02550-4.","journal-title":"Virol J"},{"key":"456_CR169","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.omtm.2021.04.003","volume":"21","author":"SL Khatwani","year":"2021","unstructured":"Khatwani SL, Pavlova A, Pirot Z. Anion-exchange HPLC assay for separation and quantification of empty and full capsids in multiple adeno-associated virus serotypes. Mol Ther Methods Clin Dev. 2021;21:548\u201358. https:\/\/doi.org\/10.1016\/j.omtm.2021.04.003.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"456_CR170","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2021.08.002","volume":"23","author":"LF Barnes","year":"2021","unstructured":"Barnes LF, Draper BE, Chen YT, Powers TW, Jarrold MF. Quantitative analysis of genome packaging in recombinant AAV vectors by charge detection mass spectrometry. Mol Ther Methods Clin Dev. 2021;23:87\u201397. https:\/\/doi.org\/10.1016\/j.omtm.2021.08.002.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3\u20134","key":"456_CR171","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1089\/hum.2021.123","volume":"33","author":"H Meng","year":"2022","unstructured":"Meng H, Sorrentino M, Woodcock D, O\u2019Riordan C, Dhawan V, Verhagen M, et al. Size exclusion chromatography with dual wavelength detection as a sensitive and accurate method for determining the empty and full capsids of recombinant adeno-associated viral vectors. Hum Gene Ther. 2022;33(3\u20134):202\u201312. https:\/\/doi.org\/10.1089\/hum.2021.123.","journal-title":"Hum Gene Ther"},{"issue":"11\u201312","key":"456_CR172","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1089\/hum.2023.169","volume":"35","author":"X Qin","year":"2024","unstructured":"Qin X, Yu Q, Li X, Jiang W, Shi X, Hou W, et al. Methodological validation of sedimentation velocity analytical ultracentrifugation method for adeno-associated virus and collaborative calibration of system suitability substance. Hum Gene Ther. 2024;35(11\u201312):401\u201311. https:\/\/doi.org\/10.1089\/hum.2023.169.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"456_CR173","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020;38(7):824\u201344. https:\/\/doi.org\/10.1038\/s41587-020-0561-9.","journal-title":"Nat Biotechnol"},{"key":"456_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2023.100491","volume":"28","author":"X Wang","year":"2023","unstructured":"Wang X, Xu G, Johnson WA, Qu Y, Yin D, Ramkissoon N, et al. Long sequence insertion via CRISPR\/Cas gene-editing with transposase, recombinase, and integrase. Curr Opin Biomed Eng. 2023;28:100491. https:\/\/doi.org\/10.1016\/j.cobme.2023.100491.","journal-title":"Curr Opin Biomed Eng"},{"issue":"10","key":"456_CR175","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","volume":"42","author":"M An","year":"2024","unstructured":"An M, Raguram A, Du SW, Banskota S, Davis JR, Newby GA, et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat Biotechnol. 2024;42(10):1526\u201337. https:\/\/doi.org\/10.1038\/s41587-023-02078-y.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"456_CR176","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41565-024-01851-7","volume":"20","author":"S Ling","year":"2025","unstructured":"Ling S, Zhang X, Dai Y, Jiang Z, Zhou X, Lu S, et al. Customizable virus-like particles deliver CRISPR-Cas9 ribonucleoprotein for effective ocular neovascular and Huntington\u2019s disease gene therapy. Nat Nanotechnol. 2025;20(4):543\u201353. https:\/\/doi.org\/10.1038\/s41565-024-01851-7.","journal-title":"Nat Nanotechnol"},{"key":"456_CR177","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.omtn.2023.08.018","volume":"33","author":"T Lan","year":"2023","unstructured":"Lan T, Chen H, Tang C, Wei Y, Liu Y, Zhou J, et al. Mini-PE, a prime editor with compact Cas9 and truncated reverse transcriptase. Mol Ther Nucleic Acids. 2023;33:890\u20137. https:\/\/doi.org\/10.1016\/j.omtn.2023.08.018.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"456_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28358-w","volume":"13","author":"P Silva-Pinheiro","year":"2022","unstructured":"Silva-Pinheiro P, Nash PA, Van Haute L, Mutti CD, Turner K, Minczuk M. In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue. Nat Commun. 2022;13(1):750. https:\/\/doi.org\/10.1038\/s41467-022-28358-w.","journal-title":"Nat Commun"},{"issue":"3","key":"456_CR179","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41587-022-01486-w","volume":"41","author":"S Lee","year":"2023","unstructured":"Lee S, Lee H, Baek G, Kim JS. Precision mitochondrial DNA editing with high-fidelity DddA-derived base editors. Nat Biotechnol. 2023;41(3):378\u201386. https:\/\/doi.org\/10.1038\/s41587-022-01486-w.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"456_CR180","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cell.2023.11.035","volume":"187","author":"SI Cho","year":"2024","unstructured":"Cho SI, Lim K, Hong S, Lee J, Kim A, Lim CJ, et al. Engineering TALE-linked deaminases to facilitate precision adenine base editing in mitochondrial DNA. Cell. 2024;187(1):95-109.e26. https:\/\/doi.org\/10.1016\/j.cell.2023.11.035.","journal-title":"Cell"},{"issue":"3","key":"456_CR181","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41587-023-01791-y","volume":"42","author":"Z Yi","year":"2024","unstructured":"Yi Z, Zhang X, Tang W, Yu Y, Wei X, Zhang X, et al. Strand-selective base editing of human mitochondrial DNA using mitoBEs. Nat Biotechnol. 2024;42(3):498\u2013509. https:\/\/doi.org\/10.1038\/s41587-023-01791-y.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"456_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56734-9","volume":"16","author":"Y Xiong","year":"2025","unstructured":"Xiong Y, Su Y, He R, Han X, Li S, Liu M, et al. EXPERT expands prime editing efficiency and range of large fragment edits. Nat Commun. 2025;16(1):1592. https:\/\/doi.org\/10.1038\/s41467-025-56734-9.","journal-title":"Nat Commun"},{"issue":"1","key":"456_CR183","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41592-024-02502-4","volume":"22","author":"A Cirincione","year":"2025","unstructured":"Cirincione A, Simpson D, Yan W, McNulty R, Ravisankar P, Solley SC, et al. A benchmarked, high-efficiency prime editing platform for multiplexed dropout screening. Nat Methods. 2025;22(1):92\u2013101. https:\/\/doi.org\/10.1038\/s41592-024-02502-4.","journal-title":"Nat Methods"},{"issue":"1","key":"456_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29339-9","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Zhou L, Gao BQ, Li G, Wang X, Wang Y, et al. Highly efficient prime editing by introducing same-sense mutations in pegRNA or stabilizing its structure. Nat Commun. 2022;13(1):1669. https:\/\/doi.org\/10.1038\/s41467-022-29339-9.","journal-title":"Nat Commun"},{"issue":"12","key":"456_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110946","volume":"301","author":"R Ho\u0142ubowicz","year":"2025","unstructured":"Ho\u0142ubowicz R, Gao F, Du SW, Rodrigues Menezes C, Zhang J, Ho\u0142ubowicz MW, et al. Scalable purification enables high-quality virus-like particles for therapeutic translation. J Biol Chem. 2025;301(12):110946. https:\/\/doi.org\/10.1016\/j.jbc.2025.110946.","journal-title":"J Biol Chem"},{"issue":"4","key":"456_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102719","volume":"36","author":"IR Brooks","year":"2025","unstructured":"Brooks IR, Graham C, Kazemizadeh A, Jack\u00f3w-Malinowska J. Prime editing in mammals: from promise to practicalities. Mol Ther Nucleic Acids. 2025;36(4):102719. https:\/\/doi.org\/10.1016\/j.omtn.2025.102719.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"456_CR187","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41587-024-02437-3","volume":"43","author":"K Chen","year":"2025","unstructured":"Chen K, Han H, Zhao S, Xu B, Yin B, Lawanprasert A, et al. Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR-Cas9 ribonucleoprotein. Nat Biotechnol. 2025;43(9):1445\u201357. https:\/\/doi.org\/10.1038\/s41587-024-02437-3.","journal-title":"Nat Biotechnol"},{"issue":"6701","key":"456_CR188","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.adm8386","volume":"384","author":"Q Huang","year":"2024","unstructured":"Huang Q, Chan KY, Wu J, Botticello-Romero NR, Zheng Q, Lou S, et al. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Science. 2024;384(6701):1220\u20137. https:\/\/doi.org\/10.1126\/science.adm8386.","journal-title":"Science"},{"key":"456_CR189","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1089\/hum.2024.035","volume":"35","author":"SQ Liang","year":"2024","unstructured":"Liang SQ, Navia AW, Ramseier M, Zhou X, Martinez M, Lee C, et al. AAV5 delivery of CRISPR\/Cas9 mediates genome editing in the lungs of young rhesus monkeys. Hum Gene Ther. 2024;35:814\u201324. https:\/\/doi.org\/10.1089\/hum.2024.035.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"456_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101536","volume":"33","author":"R Duba-Kiss","year":"2025","unstructured":"Duba-Kiss R, Hampson DR. Early postnatal expression mitigates immune responses to Cas9 in the murine central nervous system. Mol Ther Methods Clin Dev. 2025;33(3):101536. https:\/\/doi.org\/10.1016\/j.omtm.2025.101536.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"456_CR191","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41587-024-02467-x","volume":"43","author":"A Raguram","year":"2025","unstructured":"Raguram A, An M, Chen PZ, Liu DR. Directed evolution of engineered virus-like particles with improved production and transduction efficiencies. Nat Biotechnol. 2025;43(10):1635\u201347. https:\/\/doi.org\/10.1038\/s41587-024-02467-x.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"456_CR192","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1093\/nar\/gkae428","volume":"52","author":"O Yaish","year":"2024","unstructured":"Yaish O, Orenstein Y. Generating, modeling and evaluating a large-scale set of CRISPR\/Cas9 off-target sites with bulges. Nucleic Acids Res. 2024;52(12):6777\u201390. https:\/\/doi.org\/10.1093\/nar\/gkae428.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"456_CR193","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BKE, et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021;384(3):252\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2031054.","journal-title":"N Engl J Med"},{"issue":"5","key":"456_CR194","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","volume":"26","author":"E Lou","year":"2025","unstructured":"Lou E, Choudhry MS, Starr TK, Folsom TD, Bell J, Rathmann B, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 2025;26(5):559\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(25)00083-X.","journal-title":"Lancet Oncol"},{"key":"456_CR195","doi-asserted-by":"publisher","unstructured":"Li JM, Huang J, Liao Y, Hu T, Wang CL, Zhang WZ, et al. Gene and RNA editing: Revolutionary approaches to treating diseases. MedComm (2020). 2025;6(10):e70389. https:\/\/doi.org\/10.1002\/mco2.70389.","DOI":"10.1002\/mco2.70389"},{"issue":"7794","key":"456_CR196","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578(7794):229\u201336. https:\/\/doi.org\/10.1038\/s41586-020-1978-5.","journal-title":"Nature"},{"issue":"7","key":"456_CR197","doi-asserted-by":"publisher","DOI":"10.3390\/genes15070863","volume":"15","author":"R Kansal","year":"2024","unstructured":"Kansal R. The CRISPR-Cas system and clinical applications of CRISPR-based gene editing in hematology with a focus on inherited germline predisposition to hematologic malignancies. Genes (Basel). 2024;15(7):863. https:\/\/doi.org\/10.3390\/genes15070863.","journal-title":"Genes (Basel)"},{"issue":"4","key":"456_CR198","doi-asserted-by":"publisher","DOI":"10.3390\/genes14040919","volume":"14","author":"S Wu","year":"2023","unstructured":"Wu S, Xue Q, Qin X, Wu X, Kim P, Chyr J, et al. The potential regulation of A-to-I RNA editing on genes in Parkinson\u2019s disease. Genes. 2023;14(4):919. https:\/\/doi.org\/10.3390\/genes14040919.","journal-title":"Genes"},{"issue":"22","key":"456_CR199","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223582","volume":"11","author":"D Dafou","year":"2022","unstructured":"Dafou D, Kanata E, Pettas S, Bekas N, Dimitriadis A, Kempapidou G, et al. RNA editing alterations define disease manifestations in the progression of experimental autoimmune encephalomyelitis (EAE). Cells. 2022;11(22):3582. https:\/\/doi.org\/10.3390\/cells11223582.","journal-title":"Cells"},{"key":"456_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123756","volume":"376","author":"CW Huang","year":"2025","unstructured":"Huang CW, Zhang WZ, Liao Y, Hu T, Li JM, Wang CL. A targeted approach: gene and RNA editing for neurodegenerative disease treatment. Life Sci. 2025;376:123756. https:\/\/doi.org\/10.1016\/j.lfs.2025.123756.","journal-title":"Life Sci"},{"issue":"6437","key":"456_CR201","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1126\/science.aav9973","volume":"364","author":"E Zuo","year":"2019","unstructured":"Zuo E, Sun Y, Wei W, Yuan T, Ying W, Sun H, et al. Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science. 2019;364(6437):289\u201392. https:\/\/doi.org\/10.1126\/science.aav9973.","journal-title":"Science"},{"issue":"5","key":"456_CR202","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2174\/156652307782151425","volume":"7","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther. 2007;7(5):316\u201324. https:\/\/doi.org\/10.2174\/156652307782151425.","journal-title":"Curr Gene Ther"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00456-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00456-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00456-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:19:53Z","timestamp":1776863993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00456-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":202,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00456-x","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}